Cantor Fitzgerald reiterated an Overweight rating and $17.00 price target on Horizon Pharma (NASDAQ: HZNP). There has been considerable debate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE